Taysha Gene Therapies Inc
NASDAQ:TSHA
Operating Margin
Taysha Gene Therapies Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Taysha Gene Therapies Inc
NASDAQ:TSHA
|
571.1m USD |
-1 226%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
330.3B USD |
30%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
155.1B USD |
25%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
135.6B USD |
38%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.5B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
118.4B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
53.1B USD |
29%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
39.9B USD |
-5%
|
Taysha Gene Therapies Inc
Glance View
Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas and currently employs 178 full-time employees. The company went IPO on 2020-09-24. The firm is focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). Its portfolio of gene therapy candidates targets a range of neurological indications across three distinct therapeutic categories: neurodegenerative diseases, neurodevelopmental disorders and genetic epilepsies. Its product candidates include TSHA-101, which is being developed for the treatment of giant axonal neuropathy (GAN); TSHA-102, a neurodevelopmental disorder product candidate, which is being developed for the treatment of Rett syndrome; TSHA-118, which is a AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter, and TSHA-105, a gene replacement therapy for the treatment of SLC13A5 deficiency.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Taysha Gene Therapies Inc's most recent financial statements, the company has Operating Margin of -1 225.8%.
You don't have any saved screeners yet